secwatch.observer — SEC 8-K summary
======================================

Issuer:     Black Diamond Therapeutics, Inc. (BDTX)
CIK:        0001701541
Form:       8-K
Filed at:   2026-08-05T20:02:17+00:00
Accession:  0001701541-26-000023
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Black Diamond Therapeutics Q2 2026 net loss $9.9M; silevertinib shows 60% ORR in NSCLC
--------------------------------------------------------------------------------

- Cash, equivalents, and investments $110.5M as of June 30, 2026; runway into 2H 2028.
- Net loss $9.9M vs $10.6M in Q2 2025; R&D expenses $7.4M, G&A $4.7M.
- Phase 2 silevertinib in frontline non-classical EGFRm NSCLC: ORR 60%, CNS ORR 86%, median PFS 15.2 months.
- No patients developed de novo brain metastases; 53% remain on therapy, longest 23.5 months.
- FDA feedback on pivotal path for silevertinib in frontline NSCLC expected Q4 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701541/000170154126000023/0001701541-26-000023-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701541/000170154126000023/bdtx-20260805.htm
  HTML page:      https://secwatch.observer/filing/0001701541-26-000023

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer